Double discovery boosts global quest for leukaemia cures

Snowdome-supported researchers at Peter MacCallum Cancer Centre have discovered how a form of leukaemia fights back against a ground-breaking treatment, providing vital new leads on how to outwit the deadly disease. Acute Myeloid Leukaemia (AML) stem cells are particularly aggressive, insidious and nimble. Knowing how they respond when under attack enables researchers to devise interventions … Continued

Snowdome supports epigenetic BET inhibitors clinical trial

As today is International Clinical Trials Day (commemorating 20 May 1747, the day on which James Lind started his famous trial comparing treatments for scurvy), Snowdome is proud to share the following links to articles that appeared in the media today. The trial in the spotlight of all articles is supported by Snowdome funding. Consultant haematologists … Continued

recently approved research projects

Over the last 9 months, Snowdome’s funding efforts have been concentrated on directing just over $1,000,000 into epigenetic treatments for Australians with blood cancers. Snowdome has worked with several passionate donors to invest over $750,000 and has successfully secured $311,000 in matched funding through the Victorian Cancer Agency. A wonderful model of ‘government & philanthropy’ … Continued

supporting ‘global best practice’

Throughout 2013/14, Snowdome was successful in joining several like-minded major donors* to establish the Centre of Research Excellence in Myeloma (CRE-M) in Melbourne. This $3million investment will support a global best practice research approach in ‘personalised or precision medicine’ which, according to reports from the U.S. and Canada, is an emerging approach for the treatment … Continued

an update on recent accomplishments

We are proud to share that 215 Australian blood cancer patients have gained access to new, cutting-edge therapies since Snowdome formed in 2010. This year has been a record-breaking year in fund raising for Snowdome, and it has also been a record breaking year in granting funds. Snowdome’s ability to quickly fund strategically important projects … Continued

A Researcher’s Insight – Azacitidine/Eltrombopag study

In a final analysis of the Peter Mac sponsored Azacitidine/Eltrombopag study, haematologist and research fellow, Dr Michael Dickinson, targets myelodysplastic syndromes and gives us a lay summary of the purpose of the trial.  Myelodysplastic syndromes are a group of conditions that lead to ineffective production of normal blood cells by the bone marrow. Patients present … Continued

‘making hope real’ for patients with MDS

In June this year at the European Haematology Association meeting in Italy, Dr Melita Kenealy, project manager of the Victorian Epigenetics Group, presented the first results of her recently led, large Australian study for patients with Myelodysplastic syndromes. Here is a brief summary of her report, “First Analysis ALLG MDS4 Study”:- ‘Making hope real’ for … Continued